Back Finan, B, Ma, T, Ottaway, M (20 Oct 2013) 'Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans', Science Translational Medicine , 5/209, 2-9a151
Document everything including shipping time, packaging quality, and documentation accuracy
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
"Companies have to study this
Preclinical models show that GLP-1 RAs reduce amyloid- plaque deposition, dampen neuroinflammation, and enhance synaptic plasticity
Zinman B, Aroda VR, Buse JB, et al